Novo Nordisk turns to Evotec to build early-stage pipeline for diabetes, obesity drugs
The European discovery outfit at Evotec has signed up another major league player in biopharma, and they’re prepping an early-stage pipeline right where their partner is most carefully focused.
Novo Nordisk is stepping up to work with Evotec this time. The scientists at Evotec will go to work building a preclinical pipeline of small molecules primarily concentrating on diabetes and obesity — where Novo makes its money and plans to expand. And NASH, cardiovascular diseases and diabetic kidney disease are all on the menu.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
